The U.S. Department of Justice’s Antitrust Division, joined by the Ohio Attorney General, has filed a civil antitrust suit against OhioHealth, alleging the health system used contracting practices that unlawfully restricted competition and increased healthcare costs. The case, United States of America et al v. OhioHealth Corporation, puts a spotlight on how enforcers are continuing to scrutinize not just mergers, but also the day-to-day terms health systems negotiate with commercial payers.

That distinction matters. In recent years, antitrust attention in healthcare has often centered on consolidation and acquisition activity. This lawsuit signals that regulators remain equally focused on post-merger or standalone contracting behavior—especially provisions that allegedly limit insurers’ ability to steer patients, design networks, or create lower-cost benefit options that could advantage rival providers. For hospitals and integrated systems, the government’s theory underscores that contracting practices once viewed as aggressive but routine may now be framed as exclusionary conduct.

For litigators, the case is worth watching for how the government pleads competitive harm in a healthcare-services market without relying on a merger challenge. The complaint may offer a roadmap for future enforcement actions targeting payer/provider agreements, including provisions involving steering, tiering, and network design. It may also provide insight into how federal and state enforcers coordinate in civil antitrust matters when local healthcare markets are at issue.

For in-house counsel and compliance teams, the message is practical: hospital contract templates, payer negotiations, and internal sales strategies may deserve renewed antitrust review. Clauses that affect insurer flexibility, patient incentives, or rival access to commercially important networks can create risk even absent a headline-grabbing transaction. Compliance teams should also note the broader enforcement environment, where healthcare pricing and access remain politically and economically sensitive issues.

The filing against OhioHealth may become an important test case for courts evaluating whether provider contract restrictions cross the line from hard bargaining into unlawful restraints on competition. Legal departments representing health systems, payers, and provider groups should monitor the docket closely, both for the court’s treatment of the alleged conduct and for clues about where antitrust enforcers may look next. The Southern District of Ohio docket is available here: United States of America et al v. OhioHealth Corporation.

The antitrust challenge to Live Nation and Ticketmaster remains one of the most closely watched business cases in the country, even as reports indicate the U.S. Department of Justice reached a tentative settlement with the company in March 2026. The reason is straightforward: a broad coalition of states is still pressing forward, ensuring that the litigation continues to shape how courts, regulators, and the live-entertainment industry think about market power, vertical integration, and consumer harm.

The case, pending in the Southern District of New York as United States of America et al v. Live Nation Entertainment, Inc. et al, targets practices that have long drawn criticism from artists, venues, fans, and policymakers: ticketing fees, exclusive venue arrangements, and the combined influence that comes from operating both ticketing platforms and concert promotion businesses. Even if the federal government narrows its claims or remedies through settlement, the states’ continued involvement means the core allegations remain live and potentially trial-bound.

For antitrust lawyers, the case is a major test of modern enforcement strategy. It raises familiar but still evolving questions about how to prove exclusionary conduct in platform-driven markets, how to measure competitive effects beyond headline prices, and what remedies are appropriate when a dominant firm operates across multiple levels of a supply chain. Structural relief, conduct restrictions, and compliance oversight all remain part of the conversation.

For in-house counsel and compliance teams, the litigation is a reminder that partial resolution with one set of enforcers may not end exposure. Parallel federal and state actions can create different timelines, different remedy demands, and continuing discovery burdens. Companies with exclusive-dealing provisions, bundled service offerings, or vertically integrated distribution models will be watching closely for signals about where enforcers draw the line.

The matter also has broader significance beyond entertainment. A ruling or settlement framework here could influence how regulators approach dominant intermediaries in other industries, particularly where access to customers depends on a gatekeeper platform. That makes the docket worth close attention not just for antitrust specialists, but for litigators advising any company facing scrutiny over contractual lockups, fee structures, or ecosystem control.

As the case develops, the filings in the SDNY action will remain essential reading for legal professionals tracking the next phase of antitrust enforcement and the practical limits of settlement in high-profile, multi-sovereign cases.